医学
胺碘酮
心脏病学
心源性猝死
内科学
射血分数
室性心动过速
心力衰竭
药品
抗心律失常药
决奈达隆
重症监护医学
猝死
临床实习
心房颤动
药理学
家庭医学
作者
Luigi Pannone,Giuseppe D’Angelo,Simone Gulletta,Giulio Falasconi,Luigia Brugliera,Antonio Frontera,Lorenzo Cianfanelli,Luca Baldetti,Paolo Ossola,Francesco Melillo,Gabriele De Blasi,Lorenzo Malatino,Giovanni Landoni,Alberto Margonato,Paolo Della Bella,Daniele Zacchetti,Pasquale Vergara
标识
DOI:10.31083/j.rcm2204143
摘要
Ventricular arrhythmias still represent an important cause of morbidity and mortality, especially in patients with heart failure and reduced left ventricular ejection fraction. Amiodarone is a Class III Vaughan-Williams anti-arrhythmic drug widely used in ventricular arrhythmias for its efficacy and low pro-arrhythmogenic effect. On the other hand, a significant limitation in its use is represented by toxicity. In this review, the pharmacology of the drug is discussed to provide the mechanistic basis for its clinical use. Moreover, all the latest evidence on its role in different clinical settings is provided, including the prevention of sudden cardiac death, implanted cardioverter defibrillators, ischemic and non-ischemic cardiomyopathies. A special focus is placed on everyday clinical practice learning points, such as dosage, indications, and contraindications from the latest guidelines.
科研通智能强力驱动
Strongly Powered by AbleSci AI